G6PD and cancer: Thus, it has been shown that suppressing glucose-6-phosphate dehydrogenase (G6PD) using shRNA or an inhibitor, either as single agents or in combination, sensitized paclitaxel-resistant cancer cells to paclitaxel treatment and thereby improved its therapeutic efficacy via regulation of the GSTP1 expression [28].